Genocea Biosciences Obtains $35,000,000 Series B Funding Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f191bd00-7f32-4448-8d79-a77d2fa63238&Preview=1
Date 1/3/2011
Company Name Genocea Biosciences
Mailing Address 161 First Street Cambridge, MA 02142
Company Description Genocea was founded in 2006 based on technology from University of California at Berkeley and Harvard Medical School. Infectious diseases are the third leading cause of death each year in the United States and the world’s leading killer of children and young adults, accounting for more than 14 million deaths annually. In addition, numerous infectious diseases, while not major killers, cause chronic disability for millions and lead to tens of billions of dollars in excess healthcare costs. Many infectious diseases, such as malaria and tuberculosis (two of the top five global killers) as well as chlamydia (the most frequently reported bacterial sexually transmitted disease in the United States), are caused by pathogens that are capable of growing within human cells (intracellular pathogens). Despite the devastating health and economic impact of these diseases, and in spite of significant efforts to develop vaccines, no effective vaccines currently exist against these or a multitude of ot
Proceeds Purposes Proceeds will support Genocea as it enters clinical development for its lead program, a therapeutic vaccine for herpes simplex virus type 2 (HSV-2) infections. Genocea will also use funds to advance its deep research pipeline, including prophylactic vaccine programs addressing Chlamydia trachomatis, Streptococcus pneumoniae, HSV-2 and Plasmodium falciparum (malaria).
M&A Terms
Venture Investor Johnson & Johnson Development Corporation